Crossmark

Assessing the Evidence for Neoadjuvant Chemotherapy in Patients with Resectable Pancreatic Adenocarcinoma Using the Robustness of Inference to Replacement

Crossref DOI link: https://doi.org/10.1245/s10434-026-19443-1

Published Online: 2026-03-12

Published Print: 2026-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cher, Benjamin A. Y.

Lin, Qinyun

Frank, Kenneth A.

Weber, Sharon M.

Minter, Rebecca M.

Balentine, Courtney J.

Zafar, Syed Nabeel https://orcid.org/0000-0003-3843-9687
Funding

Funding for this research was provided by:

AHRQ (R01HS029874)

Department of Education (R305D220022)

NIH (T32 DC009401)

NIA (K76AG068515)
License Information

Text and Data Mining valid from 2026-03-12

Version of Record valid from 2026-03-12
More Information

Article History

Received: 23 January 2026

Accepted: 22 February 2026

First Online: 12 March 2026

Disclosure

: There are no conflicts of interest to disclose.

Document is current

Any future updates will be listed below